Enanta Pharmaceuticals (ENTA) Corporate presentation summary

Company overview and financials

• Focuses on small molecule drugs for virology and immunology, with all compounds discovered in-house leveraging medicinal chemistry expertise.

• Founded in 1995 and public since 2013, maintains a strong cash position with $241.9M as of December 31, 2025.

• Generates ongoing HCV royalties and has two approved products with AbbVie, curing over 1 million Hepatitis C patients.

Pipeline and clinical programs

• Pipeline includes programs in virology (HCV, RSV, COVID-19) and immunology (Type 2 immune diseases, CSU, atopic dermatitis).

• RSV portfolio features zelicapavir (N-protein inhibitor) and EDP-323 (L-protein inhibitor), both with Fast Track FDA designation.

• Immunology pipeline targets KIT, MRGPRX2, and STAT6, aiming for best-in-class oral therapies for diseases like CSU and atopic dermatitis.

RSV clinical results and development

• Zelicapavir showed positive Phase 2b results in high-risk adults, reducing symptom duration, hospitalization rates, and viral load.

• Pediatric Phase 2 study demonstrated antiviral effect and reduced symptom duration, supporting further development.

• EDP-323 achieved 85-87% reduction in viral load and 97-98% reduction in viral culture in a human challenge model, with good safety.